Form 4: Zevra Therapeutics Director Corey Michael Watton Reports Transaction
SEC Form 4 Filing
Director Corey Michael Watton reports acquisition and disposal of Zevra Therapeutics common stock on October 11, 2024.
Summary
- On October 11, 2024, Corey Michael Watton, a director of Zevra Therapeutics, engaged in a transaction involving the company's common stock.
- Watton acquired 500 shares at a price of $7.9153 per share.
- Watton also disposed of 1,500 shares.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholders' perception of the company, depending on their interpretation of the director's actions.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of stock acquisition and disposal transaction. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.